newsfilter
← Earnings
Earnings Releases·

Lexeo Therapeutics — Third Quarter 2026 Earnings Summary

  • **Financial Results:** Net loss widened to $38.3 million ($0.43/share) for Q3 2026 from $20.3 million ($0.33/share) in the prior year, driven by a 119% increase in R&D expenses to $34.5 million following the September 2026 acquisition of Mantle Therapeutics; cash and investments remain robust at $219.1 million, extending the operational runway into 2028.
  • **Clinical Progress:** Interim Phase I/II data for LX2020 in PKP2-ACM demonstrated an 80% mean reduction in NSVT and 44% reduction in PVCs in high-dose cohorts, with preliminary evidence of cardiac function stabilization and dose-dependent protein expression increases.
  • **Regulatory Outlook & Strategy:** The FDA has indicated openness to using guideline-defined NSVT as a primary surrogate endpoint for accelerated approval of LX2020; the company plans to finalize pivotal study design in H1 2027 and initiate the pivotal study in H2 2027.
  • **Corporate Governance:** The company appointed Toby Schilke as an independent director and confirmed the achievement of a development milestone related to the LX2006 pivotal study initiation during the quarter.
Company
LEXEO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology